Biological product containing transcription factor for inducing reprogramming of fibroblasts into cochlear spiral neuronal cells and application thereof

The combined transcription factors of Ascl1, Pou4f1 and Myt1l are induced in fibroblasts, which solves the problems of low efficiency and insufficient maturity in the existing technology, and realizes efficient reprogramming of cochlear spiral neuron cells and Regeneration improves the functional recovery of auditory neurons.

CN118955679APending Publication Date: 2024-11-15NANJING UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411066481.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing combination of transcription factors is inefficient and decreases with age when inducing fibroblast reprogramming into cochlear helical neuronal cells, and the induced cells exhibit only general neuronal characteristics and lack mature SGN characteristics and functions.

Method used

Using the combination of three transcription factors, Ascl1, Pou4f1 and Myt1l, these genes are expressed in fibroblasts by constructing viral vectors, inducing their conversion into cochlear spiral neuron cells, and promoting their maturation through specific culture media and growth factor environments. and regeneration.

Benefits of technology

The efficient induction of mature cochlear spiral neuron cells was achieved, showing marker expression and electrophysiological characteristics similar to mature SGN, improving the regeneration and functional recovery of cochlear spiral neurons, and providing a new method to treat hearing loss.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955679A_ABST
    Figure CN118955679A_ABST
Patent Text Reader

Abstract

The invention provides a biological product containing a transcription factor for inducing fibroblasts to be reprogrammed into neuronal cells. The transcription factor comprises one or more of Ascl1, Pou4f1 and Myt1l; the invention further discloses a using method and application of the device. The application has the following advantages: the invention provides a method for regenerating cochlear spiral neurons through combined expression of transcription factors Ascl1, Pou4f1 and Myt1l, and also relates to a combination of Ascl1, Pou4f1 and Myt1l proteins, which can improve sensorineural hearing loss symptoms caused by cochlear spiral neurons degeneration and / or damage, and can improve hearing loss of cochlear spiral neurons. The hearing loss symptom caused by hearing nerve damage can be relieved by regenerating the SGN-like cells, the problem of poor prognosis of a patient suffering from hearing nerve damage caused by artificial cochlea implantation can be solved, and a new method and preparation are provided for clinical treatment of hearing loss.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biotechnology, and is concerned with biological products containing transcription factors for inducing fibroblasts to reprogram into cochlear spiral neuron cells and applications thereof. Background Art

[0002] Pioneer and lineage-specific transcription factors (TFs) can induce fibroblasts or glial cells to differentiate into different neuronal subtypes.

[0003] Mouse embryonic fibroblasts (MEFs) are widely distributed, easy to obtain in large quantities, and have strong proliferation capacity. Studies have reported that the combined use of Forskolin, ISX9, I-BET151, and CHIR99021 (FIBC) can effectively induce MEFs and astrocytes to differentiate into neurons. Therefore, MEFs are a good cell model for high-throughput screening of TFs for neuronal reprogramming.

[0004] It has been reported that TFs Ascl1 / Nd1 reprogram sensory epithelia and glial cells into neurons in vitro. Other studies have also found that transcription factors Ng1 / Nd1 or Lin28 can reprogram Plp1-positive glial cells into cochlear spiral neurons (SGNs) in mice. Among them, the neural cells induced by transcription factors Ng1 / Nd1 expressed neuronal and SGN markers, while the expression of glial cell markers decreased. In the SGN injury mouse model, Lin28 overexpression can induce cochlear glial cells to express neural stem cell markers, and then these glial cells will be converted into neurons. However, the reprogramming efficiency of Ng1 / Nd1 and Lin28 is very limited, and it decreases significantly with age. In addition, the SGN-like cells induced in the current study only show general neuronal characteristics and lack the characteristics and functions of mature SGNs. Therefore, the combination of transcription factors that induce functional SGN reprogramming needs further study and optimization. Summary of the invention

[0005] In view of the above-mentioned technical limitations, the present application proposes a biological product containing transcription factors for inducing fibroblasts to reprogram into cochlear spiral neuron cells and its application; it overcomes the deficiencies and defects mentioned in the background technology.

[0006] To achieve the above objectives, this application adopts the following technical solutions:

[0007] The inventive point of the present application is to provide a biological product containing transcription factors for inducing fibroblasts to reprogram into neuronal cells, wherein the transcription factors include one or more of Ascl1, Pou4f1 and Myt1l.

[0008] Optionally, in the above-mentioned biological product, the transcription factor is a gene or a protein expressed by it; and the neuronal cells are cochlear spiral neuronal cells.

[0009] The combinations of the three genes and their proteins are: Ascl1 gene and its protein alone, Pou4f1 gene and its protein alone, Myt1l gene and its protein alone, Ascl1 gene and its protein in combination with Pou4f1 gene and its protein, Pou4f1 gene and its protein in combination with Myt1l gene and its protein, Ascl1 gene and its protein in combination with Myt1l gene and its protein, and Ascl1 gene and its protein + Pou4f1 gene and its protein + Myt1l gene and its protein in combination.

[0010] Optionally, in the above-mentioned biological product, the nucleotide sequence of the Ascl1 gene is shown as SEQ ID No.1, and the amino acid sequence of its protein is shown as SEQ ID No.4.

[0011] Optionally, in the above-mentioned biological product, the nucleotide sequence of the Pou4f1 gene is shown as SEQ ID No.2, and the amino acid sequence of its protein is shown as SEQ ID No.5.

[0012] Optionally, in the above-mentioned biological product, the nucleotide sequence of the Myt11 gene is shown as SEQ ID No.3, and the amino acid sequence of its protein is shown as SEQ ID No.6.

[0013] SEQ ID No.1:

[0014] atggaaagcagcggcaaaatggaaagcggcgcgggccagcagccgcagccgccgcagccgtttctgccgccggcggcgtgcttttttgcgaccgcggcggcggcggcggcggcggcggcggcggcggcgcagagcgcgcagcagcagcagccgcaggcgccgccgcagcaggcgccgcagctgagcccggtggcggatagccagccgagcggcggcggccataaaagcgcggcgaaacaggtgaaacgccagcgcagcagcagcccggaactgatgcgctgcaaacgccgcctgaactttagcggctttggctatagcctgccgcagcagcagccggcggcggtggcgcgccgcaacgaacgcgaacgcaaccgcgtgaaactggtgaacctgggctttgcgaccctgcgcgaacatgtgccgaacggcgcggcgaacaaaaaaatgagcaaagtggaaaccctgcgcagcgcggtggaatatattcgcgcgctgcagcagctgctggatgaacatgatgcggtgagcgcggcgtttcaggcgggcgtgctgagcccgaccattagcccgaactatagcaacgatctgaacagcatggcgggcagcccggtgagcagctatagcagcgatgaaggcagctatgatccgctgagcccggaagaacaggaactgctggattttaccaactggttt。

[0015] SEQ ID No.2:

[0016]

[0017] SEQ ID No.3:

[0018]

[0019] SEQ ID No.4:

[0020] MESSGKMESGAGQQPQPPQPFLPPAACFFATAAAAAAAAAAAAQSAQQQQPQAPPQQAPQLSPVADSQPSGGGHKSAAKQVKRQRSSSPELMRCKRRLNFSGFGYSLPQQQPAAVARRNERERNRVKLVNLGFATLREHVPNGAANKKMSKVETLRSAVEYIRALQQLLDEHDAVSAAFQAGVLSPTISPNYSNDLNSMAGSPVSSYSSDEGSYDPLSPEEQELLDFTNWF。

[0021] SEQ ID No.5:

[0022] MMSMNSKQPHFAMHPTLPEHKYPSLHSSSEAIRRACLPTPPLQSNLFASLDETLLARAEALAAVDIAVSQGKSHPFKPDATYHTMNSVPCTSTSTVPLAHHHHHHHHHQALEPGDLLDHISSPSLALMAGAGGAGAAGGGGGAHDGPGGGGGPGGGGGPGGGGPGGGGGGGGPGGGGGGPGGGLLGGSAHPHPHMHGLGHLSHPAAAAAMNMPSGLPHPGLVAAAAHHGAAAAAAAAAAGQVAAASAAAAVVGAAGLASICDSDTDPRELEAFAERFKQRRIKLGVTQADVGSALANLKIPGVGSLSQSTICRFESLTLSHNNMIALKPILQAWLEEAEGAQREKMNKPELFNGGEKKRKRTSIAAPEKRSLEAYFAVQPRPSSEKIAAIAEKLDLKKNVVRVWFCNQRQKQKRMKFSATY。

[0023] SEQ ID No.6:

[0024]

[0025] The second invention of the present application is to provide a method for promoting the regeneration of cochlear spiral neuronal cells, comprising expressing the following exogenous transcription factors in non-neuronal cells: Ascl1, Pou4f1 and / or Myt1l.

[0026] Optionally, the above method, wherein the non-neuronal cells are fibroblasts or inner ear glial cells, specifically comprises the following steps:

[0027] S1. constructing a viral vector containing Ascl1, Pou4f1 and / or Myt1l genes, and packaging the virus using a transfection reagent, wherein the virus is a retrovirus, a lentivirus or an AAV virus; preferably a lentivirus;

[0028] S2. Cultivating donor-derived fibroblasts and infecting the donor-derived fibroblasts with the packaged virus;

[0029] S3. Inducing the donor-derived fibroblasts into cochlear spiral neuron cells in a neuron induction medium, and then culturing them in a neuron maintenance medium, wherein both the neuron induction medium and the neuron maintenance medium include small molecule compounds and growth factors that promote reprogramming;

[0030] S4. Isolate and purify the cochlear spiral neuron cells.

[0031] Optionally, in the above method, in step S3,

[0032] The neuron induction medium used in the first 6 days includes the following components: based on DMEM / F12 medium, supplemented with additives B27, N2, GlutaMax, NEAA, penicillin-streptomycin and bFGF; the content of each additive in the neuron induction medium is: 1×B27, 1×N2, 100ng / ml bFGF, 1×GlutaMax, 1×NEAA, 1×penicillin-streptomycin;

[0033] The neuron maintenance medium used in subsequent culture includes the following components: a DMEM / F12 medium and a Neurobasal Medium medium mixed in a volume ratio of 1:1, supplemented with additives B27, N2, GlutaMax, NEAA, penicillin-streptomycin, bFGF, BDNF and NT3; the content of each additive in the neuron maintenance medium is 1×B27, 1×N2, 1×GlutaMax, 1×NEAA, 1×penicillin-streptomycin, 20ng / ml bFGF, 50ng / ml BDNF and 50ng / ml NT3.

[0034] The third invention point of the present application is to provide cochlear spiral neuron cells obtained by the above method.

[0035] The fourth inventive point of the present application is to provide the use of the above-mentioned biological products in inducing fibroblasts to reprogram into neuronal cells or in preparing products for inducing fibroblasts to reprogram into neuronal cells.

[0036] The present application systematically screened transcription factors that induce SGN fate reprogramming and identified a specific transcription factor combination Ascl1 / Pou4f1 / Myt1l (APM), which can induce mouse fibroblasts to transform into mature SGNs. APM-induced SGN-like cells showed the expression of mature SGN markers (such as neurons, synapses, ion channel markers, etc.) and also showed electrophysiological properties similar to mature SGNs. Therefore, APM is a transcription factor combination that guides functional SGN fate transformation.

[0037] Compared with the prior art, this application has the following advantages:

[0038] The present invention provides a method for regenerating cochlear spiral neurons by jointly expressing transcription factors Ascl1, Pou4f1 and Myt1l, and also relates to a combination of Ascl1, Pou4f1 and Myt1l proteins, which can improve the symptoms of sensorineural hearing loss caused by degeneration and / or damage of cochlear spiral neurons (SGNs), and can also alleviate the symptoms of hearing loss caused by auditory nerve damage by regenerating SGN-like cells, and also help to improve the problem of poor prognosis of patients with auditory neuron damage after cochlear implantation, thereby providing a new method and preparation for the clinical treatment of hearing loss. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1-Figure 3 Ascl1 was shown to be a key pioneer TF promoting FIBC-induced SGN-like neuronal reprogramming.

[0040] Figure 1 A list of 33 potential reprogramming TFs, including 30 TFs and 3 negative regulators selected based on SGN development and neuronal reprogramming studies, was constructed. Lentiviruses carrying ORFs or shRNA were used to overexpress the 30 TFs and knockdown the 3 negative regulators, respectively.

[0041] Figure 2 Experimental design for the first round of transcription factor screening.

[0042] Figure 3 Immunofluorescence images of Tuj1, Map2, Syp, and Prox1 expression in Ascl1-iNs.

[0043] Figure 4-Figure 8 Shown are qPCR array and PCA analyses identifying Pou4f1, Pou4f2, and Pou4f3 as cooperating with Ascl1 to promote SGN fate transitions.

[0044] Figure 4 Schematic diagram of the neuronal reprogramming process induced by Ascl1+1 (“1” is Figure 1 Any one of the 33 reprogramming factors shown).

[0045] Figure 5 RT-qPCR gene expression analysis for lentiviral overexpression of TFs or knockdown of negative regulators.

[0046] Figure 6 Figure 2 is a heat map of qPCR arrays for Ascl1+1 lentivirus-mediated iNs- and SGN-specific gene expression 12 days after induction.

[0047] Figure 7 PCA analysis of qPCR array data of Ascl1+32 TFs or negative regulators.

[0048] Figure 8 Representative images of iNs Tuj+ at 10 days after induction.

[0049] Figure 9-Figure 16 Ascl1 / Pou4f1-induced neurons are shown to exhibit molecular features of the SGN lineage.

[0050] Fig. 9 Schematic diagram of the neuron induction process.

[0051] Fig.10 Immunofluorescence images of Ascl1 and Pou4f1 after iNs were co-infected with Ascl1 / Pou4f1.

[0052] Fig.11Immunofluorescence images of iNs (Tuj1 and Syp) on day 22 after Ascl1 / Pou4f1 induction.

[0053] Fig.12 Immunofluorescence images of iNs (Tuj1 and Map2, Tuj1 and NFH) on day 22 after Ascl1 / Pou4f1 induction.

[0054] Fig.13 Immunofluorescence images of iNs (Syn1 and GluR2) on day 22 after Ascl1 / Pou4f1 induction.

[0055] Fig.14 Immunofluorescence images of iNs (Prox1 and Tubb3-mCherry) on day 22 after Ascl1 / Pou4f1 induction.

[0056] Fig.15 The percentage of Tuj1+ neurons induced by Ascl1 alone or Ascl1 / Pou4f1; N=7-8 (7-8 random fields in 3 samples), error bars represent mean±SD, unpaired t-test, ***p<0.001.

[0057] Fig.16 The ratio of Tuj1 single-positive and Tuj1 / Syp double-positive neurons induced by Ascl1 / Pou4f1 (7-8 random fields in 3 samples).

[0058] Figure 17-Figure 20 It was shown that Ascl1 / Pou4f1-induced neurons have functional properties of sensory neurons.

[0059] Fig.17 Micrographs showing typical iNs selected for voltage clamp recordings of K+ and Na+ currents.

[0060] Fig.18 Representative traces of action potentials of iNs without electrophysiological properties.

[0061] Fig.19 Voltage clamp recordings of K+ and Na+ currents.

[0062] Fig. 20 Representative traces of action potentials in iNs at 22 dpi, with initial single-pulse electrophysiological properties.

[0063] Figure 21-24 Shown that Myt1l in combination with Ascl1 / Pou4f1 further promotes the expression of SGN markers.

[0064] Fig.21PCA analysis of qPCR array data for Ascl1 / Pou4f1+each TF or negative regulator.

[0065] Fig. 22 Heatmap of qPCR arrays for neuron- and SGN-specific gene expression 12 days after induction of Ascl1 / Pou4f1 (AP) or Ascl1 / Pou4f1 / Myt1l (APM), with differentially regulated genes marked in magenta.

[0066] Fig.23 RT-qPCR gene expression analysis of lentiviral overexpression of Ascl1, Pou4f1 and Myt1l in iNs, N=XX biological replicates, one-way ANOVA, ****p<0.0001.

[0067] Fig.24 Expression of SGN-specific genes in neurons induced by AP, APM or Myt1l alone was examined; N = XX biological replicates, two-way ANOVA, *p<0.05, ***p<0.001 and ****p<0.0001, ns not significant.

[0068] Figure 25-Figure 29 Ascl1 / Pou4f1 / Myt1l-induced neurons were shown to exhibit more mature electrophysiological properties.

[0069] Fig.25 It is a representative electrophysiological trace of a single action potential (A) or multiple action potentials (APs).

[0070] Fig.26 APM induced more neurons to (C) fire action potentials and (D) fire multiple APs; Chi-square test, *p<0.05.

[0071] Fig. 27 Voltage clamp recordings of K+ currents were performed before and after drug administration.

[0072] Fig.28 Voltage clamp recordings of Na+ currents were performed before and after drug administration.

[0073] Fig.29 Voltage clamp recordings of APs were performed before and after drug administration.

[0074] Figure 30-Figure 32 Ascl1 / Pou4f1 / Myt1l-induced neurons were shown to have glutamatergic properties and respond to glutamate stimulation.

[0075] Fig.30Figure 2 is a heat map of qPCR arrays showing the expression of glutamatergic, serotonergic, dopaminergic, cholinergic, and GABAergic markers induced by Ascl1 alone, AP, or APM in MEFs and neurons.

[0076] Fig.31 Electrophysiological recordings of APM-iNs responses to exogenous glutamate.

[0077] Fig.32 From top to bottom are immunofluorescence images of APM-iNs expressing glutamate protein markers GluA2 (GluR2), NMDAR1, and NMDAR2b.

[0078] Fig.33 Schematic diagram of the experimental process for screening APM transcription factors to promote spiral neuron reprogramming.

[0079] In the above-mentioned figures, Fig. 22 , Fig.24 , Fig.30 , Fig.32 The results of the detection experiment of spiral neuron cell markers are shown, which proves that spiral neuron cells are indeed regenerated after reprogramming.

[0080] Figure 25-29 as well as Fig.31 The electrophysiological characteristics of the regenerated spiral neuron cells were further verified, proving that the reprogrammed regenerated spiral neuron cells have normal functions. DETAILED DESCRIPTION

[0081] In order to make the purpose, technical solution and advantages of the present application more clear, the present application is further described in detail below. However, it should be understood that the description here is only used to explain the present application and is not used to limit the scope of the present application.

[0082] Unless otherwise defined, all technical terms and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present application, and the terms used herein in the specification of the present application are only for the purpose of describing specific embodiments and are not intended to limit the present application. The reagents and instruments used herein are all commercially available, and the characterization means involved can refer to the relevant descriptions in the prior art, which will not be repeated herein.

[0083] In order to further understand the present application, the present application is further described in detail below in conjunction with the best embodiment.

[0084] Example 1

[0085] Based on RNA sequencing analysis and previously reported SGNs omics data, the applicants screened 33 TFs or neuronal repressors that may regulate SGN reprogramming ( Figure 1 These TFs were cloned into lentiviral vectors and overexpressed in MEFs. First, neuronal differentiation of MEFs was induced by FIBC in the presence of 12 neuronal TFs (Ascl1, Mafb, Gata3, Brn4, Prox1, Hes6, Ng2, Nd1, Pou4f1, Pou4f2, and Runx1). Figure 2 ). Among them, the concentrations of the small molecule drug FIBC were: 20μM Forskolin, 20μM ISX9, 1–2μM I-BET151 and 10μM CHIR99021; the differentiated cells were subjected to immunofluorescence detection and qPCR analysis of relevant markers at the 8th, 18th or longer differentiation time to detect the induced effect. The results showed that Ascl1 was the only TF that had a profound effect on improving cell survival and neuronal number. In addition, in the presence of FIBC, Ascl1-induced neurons (iNs) expressed neuronal markers Tuj1 and Map2, synaptic marker Syp11 and SGN markers Prox1 and FIBC ( Figure 3 ), while the expression of Syp11 and Prox1 was not observed in iNs treated with FIBC alone. These results indicate that Ascl1 is a key pioneer TF that promotes FIBC-induced neuronal survival, maturation, and SGN fate conversion. Therefore, in subsequent screening studies, the applicants coupled Ascl1 with the remaining 32 TFs or neuronal repressors to detect potential synergistic effects on SGN reprogramming.

[0086] Example 2

[0087] Although the pioneer TF Ascl1 showed the ability to induce neuronal differentiation in the presence of FIBC, neurons induced by Ascl1 alone rarely expressed mature neuronal markers and SGN-specific markers, and small molecules were difficult to deliver and maintain in vivo. Therefore, the applicant subsequently conducted a second round of screening for TFs that promote neuronal reprogramming without small molecules but based on Ascl1.

[0088] To screen the effects of the remaining 32 TFs or repressors ( Figure 1 ), the applicants performed qPCR array analysis on iNs induced 12 days (12-day postinduction, 12dpi) ( Figure 4 TFs overexpression was confirmed by qPCR ( Figure 5). Currently, SGN lacks a recognized specific marker, so the applicant developed a SGN fate-specific qPCR array, the analysis results of which can be used as a quantitative readout to comprehensively evaluate the maturity of induced neurons and SGN characteristics. The qPCR array includes a list of 16 genes related to neuronal cell structure, synaptic transmission, ion channels, SGN-expressed genes, and fibroblast expression. Based on this list, the applicant designed a series of qPCR primers for detecting the expression of related genes, as shown in Table 1 (forward primers) and Table 2 (reverse primers).

[0089] Table 1

[0090]

[0091]

[0092]

[0093] Table 2

[0094]

[0095]

[0096] The induced neurons were collected, RNA was extracted and reverse transcribed using a 15 μL reaction system according to the manufacturer's protocol. qPCR reactions were performed on a 96-well instrument. Once expression data for selected genes in induced neurons were obtained, qPCR array heat maps were generated and principal component analysis (PCA) analysis was performed to identify specific TFs that could induce SGN expression profiles. The results showed that transcription factors of the Pou4f family, Pou5f1, Ng1, Ng2, Nd1, Scrt2, Gata3, and Myt1L, showed enhanced neuronal conversion under Ascl1-based conditions ( Figure 6 and Figure 8 ). In addition, the neuronal differentiation efficiency of the selected Ascl1+1 TF pairs was improved compared with Ascl1-iNs ( Figure 8 ). PCA results showed that the selected Ascl1+1 TF pair increased the expression of neuronal and SGN genes and decreased the expression of MEF markers ( Figure 6 ). PCA analysis also showed that Pou4f family transcription factors (Pou4f1, Pou4f2, and Pou4f3) globally promoted the gene expression profile of iNs in primary SGNs. Moreover, overexpression of Pou4f family TFs significantly increased the percentage of Tuj1+ bipolar neurons during neuronal differentiation ( Figure 7Among the Pou4f family, since the expression of Pou4f1 begins in early ear development and is maintained in mature SGNs, the applicants chose Pou4f1 for further verification.

[0097] Example 3

[0098] To detect the protein expression of markers related to neuronal differentiation and maturation in Ascl1 / Pou4f1-induced neurons (AP-iNs), the applicant performed immunocytochemical staining ( Fig. 9 Ascl1, Pou4f1, and mCherry colocalized in iNs, confirming the overexpression of Ascl1 / Pou4f1 after lentiviral infection ( Fig.10 ).

[0099] Starting from 6 dpi, iNs gradually showed neuronal morphology and expressed the neuronal marker Tuj1. As the induction time increased, iNs showed axonal elongation and neuronal maturation. At 20 dpi, Tubb3-mCherry-positive AP-iNs were observed to have neuronal axonal morphology ( Fig.11 The applicant calculated the ratio of Tubb3-mCherry positive iNs to neuronal axon morphology ( Fig.15 ). About 23% of Ascl1-ins and 76% of Ascl1 / Pou4f1-iNs were Tuj1-positive. In addition, tubb3-expressing AP-iNs were co-labeled with mature neuronal markers Syp11 and Syn1, suggesting potential synaptic maturation. Tuj1 / Syp11 double-positive neurons accounted for 72.3% of Ascl1 / Pou4f1-iNs ( Fig.16 Mature neuronal markers Map2 and NFH also colocalize with Tuj1 ( Fig.12 ). In addition, AP-iNs expressed the neuronal marker GluR2, indicating that AP-iNs are glutamatergic ( Fig.13 Importantly, AP-iNs also expressed the SGN marker Prox1, indicating that SGN fate was induced ( Fig.14 ). These findings indicate that AP is a key TF pair that promotes neuronal differentiation, maturation, and SGN fate switching.

[0100] Example 4

[0101] The applicant used whole-cell patch clamp to detect the electrophysiological properties of AP-iNs and found that at 12 dpi, AP-iNs produced K+ current and small Na+ current, but no action potential, indicating that they were not yet mature ( Figure 17-Figure 18 At 22 dpi, most neurons had typical Na+ and K+ currents, suggesting the opening of voltage-dependent sodium and potassium channels ( Fig.19). Notably, a small number of AP-iNs showed single action potential responses ( Fig. 20 ). Therefore, AP-iNs exhibited the initial functional membrane properties and electrophysiological characteristics of neurons.

[0102] Example 5

[0103] Since the electrophysiological characteristics of SGNs exhibited by AP-iNs were not mature enough, in order to obtain more mature SGN-like iNs, the applicants conducted a new round of screening. To evaluate the effects of the remaining 31 TFs or repressors, PCA and qPCR array analysis were performed on iNs at 12 dpi ( Fig.21 ). The results showed that Myt1l enhanced neuronal conversion under AP-based conditions ( Fig.21 and Fig. 22 ).

[0104] To evaluate whether Ascl1, Pou4f1, and Myt1l co-expression (APM) truly promotes the transition of cells to the mature SGN lineage, the expression of Ascl1, Pou4f1, and Myt1l in induced cells was initially verified by RT-qPCR ( Fig.23 ), and then evaluated the changing trends of auditory neuron markers at different induction time points. Snap25 and Gria2 are essential for synaptic transmission of auditory neurons. Ntrk3 is a receptor for neurotrophins and is involved in the development and survival of auditory neurons. Isl1 is a transcription factor that is essential for the development of auditory neurons. Nav1.6 is a voltage-gated sodium channel required for the generation of action potentials in auditory neurons, while Kv1.2 is a voltage-gated potassium channel that regulates membrane potential and contributes to the repolarization phase of the action potential of auditory neurons. The results showed that co-induction of APM enhanced the expression of most mature SGN markers compared with AP ( Fig.24 ).

[0105] Example 6

[0106] By using the whole-cell patch clamp technique to detect the electrophysiological characteristics of bipolar neuron morphology iNs, the applicant found that APM-iNs induced more action potentials than AP-iNs, and the proportion of cells showing mature electrophysiological characteristics was significantly higher ( Figure 25-26 ). Tetrodotoxin (TTX) is a highly toxic non-protein biotoxin belonging to the alkaloid class. TTX is a highly selective, rapidly reversible sodium channel blocker that blocks the influx of sodium ions into cells, thereby affecting the cell membrane action potential. The applicant also found that TTX treatment can inhibit the electrophysiological properties of APM-iNs ( Figure 27-Figure 29 ), indicating the presence of typical Na + channels in APM-iNs.

[0107] Example 7

[0108] qPCR array analysis showed that both AP and APM induction conditions significantly upregulated the expression of glutamatergic neuron-specific marker genes ( Fig.30 ). Electrophysiological analysis showed that APM-iNs responded to glutamate stimulation ( Fig.31 ). Immunofluorescence staining showed that various glutamatergic marker proteins were expressed in APM-iNs ( Fig.32 ). Therefore, APM-iNs showed stronger maturity in electrophysiological characteristics of auditory neurons, indicating that APM plays a key role in promoting neuronal differentiation, maturation and SGN fate transition through a key combination of transcription factors.

[0109] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions or improvements made within the spirit and principles of the present application should be included in the protection scope of the present application.

Claims

1. A biological product containing a transcription factor for inducing fibroblasts to reprogram into neuronal cells, characterized in that: The transcription factors include one or more of Ascl1, Pou4f1 and Myt11.

2. The biological product according to claim 1, characterized in that The transcription factor is a gene or a protein expressed by it; the neuron cell is a cochlear spiral neuron cell.

3. The biological product according to claim 1 or 2, characterized in that The nucleotide sequence of the Ascl1 gene is shown in SEQ ID No.1, and the amino acid sequence of its protein is shown in SEQ ID No.

4.

4. The biological product according to claim 1 or 2, characterized in that The nucleotide sequence of the Pou4f1 gene is shown in SEQ ID No.2, and the amino acid sequence of its protein is shown in SEQ ID No.

5.

5. The biological product according to claim 1 or 2, characterized in that: The nucleotide sequence of the Myt11 gene is shown in SEQ ID No.3, and the amino acid sequence of its protein is shown in SEQ ID No.

6.

6. A method for promoting the regeneration of cochlear spiral neuronal cells, comprising expressing the following exogenous transcription factors: Ascl1, Pou4f1 and / or Myt1l in non-neuronal cells.

7. The method according to claim 6, characterized in that The non-neuronal cells are fibroblasts or inner ear glial cells, and the method specifically comprises the following steps: S1. constructing a viral vector containing Ascl1, Pou4f1 and / or Myt1l genes, and packaging the virus using a transfection reagent, wherein the virus is a retrovirus, a lentivirus or an AAV virus; preferably a lentivirus; S2. Cultivating donor-derived fibroblasts and infecting the donor-derived fibroblasts with the packaged virus; S3. Inducing the donor-derived fibroblasts into cochlear spiral neuron cells in a neuron induction medium, and then culturing them in a neuron maintenance medium, wherein both the neuron induction medium and the neuron maintenance medium include small molecule compounds and growth factors that promote reprogramming; S4. Isolate and purify the cochlear spiral neuron cells.

8. The method according to claim 7, characterized in that In the step S3, The neuronal induction medium used in the first 6 days The invention comprises the following components: based on DMEM / F12 culture medium, supplemented with additives B27, N2, GlutaMax, NEAA, penicillin-streptomycin and bFGF; the content of each additive in the neuron induction culture medium is: 1×B27, 1×N2, 100ng / ml bFGF, 1×GlutaMax, 1×NEAA, 1×penicillin-streptomycin; The neuron maintenance medium used in subsequent culture is The invention comprises the following components: a DMEM / F12 culture medium and a Neurobasal Medium culture medium mixed in a volume ratio of 1:1, supplemented with additives B27, N2, GlutaMax, NEAA, penicillin-streptomycin, bFGF, BDNF and NT3; the content of each additive in the neuron maintenance culture medium is 1×B27, 1×N2, 1×GlutaMax, 1×NEAA, 1×penicillin-streptomycin, 20ng / mlbFGF, 50ng / mlBDNF and 50ng / mlNT3.

9. Cochlear spiral neuron cells obtained by the method according to any one of claims 6 to 9.

10. Use of the biological product according to any one of claims 1 to 5 in inducing reprogramming of fibroblasts into neuronal cells or in preparing a product for inducing reprogramming of fibroblasts into neuronal cells.